{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T04:18:08Z","timestamp":1743567488389,"version":"3.40.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101150"],"award-info":[{"award-number":["82101150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21YF1405300"],"award-info":[{"award-number":["21YF1405300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00417-024-06681-w","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T06:20:39Z","timestamp":1731133239000},"page":"659-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proton beam irradiation with anti-VEGF therapy for polypoidal choroidal vasculopathy: results of a 24-month, phase II randomized study"],"prefix":"10.1007","volume":"263","author":[{"given":"Wenyi","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianxin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gezhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-4722","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"6","key":"6681_CR1","doi-asserted-by":"publisher","first-page":"e806","DOI":"10.1111\/aos.14683","volume":"99","author":"S Borooah","year":"2021","unstructured":"Borooah S, Sim PY, Phatak S, Moraes G, Wu CY, Cheung CMG et al (2021) Pachychoroid spectrum disease. Acta Ophthalmol 99(6):e806\u2013e822","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"6681_CR2","doi-asserted-by":"publisher","first-page":"12052","DOI":"10.1038\/s41598-021-91589-2","volume":"11","author":"J Yoon","year":"2021","unstructured":"Yoon J, Yoon W, Na SK, Lee J, Kim CG, Kim JW et al (2021) Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci Rep 11(1):12052","journal-title":"Sci Rep"},{"issue":"5","key":"6681_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB et al (2018) Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology 125(5):708\u2013724","journal-title":"Ophthalmology"},{"issue":"1","key":"6681_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144(1):15\u201322","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"6681_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453\u20131464","journal-title":"Retina"},{"issue":"4","key":"6681_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ (2013) Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 156(4):652\u2013660","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"6681_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2012-302652","volume":"97","author":"T Hikichi","year":"2013","unstructured":"Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K et al (2013) Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol 97(5):617\u2013621","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"6681_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bjophthalmol-2013-304736","volume":"98","author":"CC Wykoff","year":"2014","unstructured":"Wykoff CC, Brown DM, Maldonado ME, Croft DE (2014) Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol 98(7):951\u2013955","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"6681_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P et al (2017) Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol 135(11):1206\u20131213","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"6681_CR10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","volume":"35","author":"CW Wong","year":"2015","unstructured":"Wong CW, Cheung CM, Mathur R, Li X, Chan CM, Yeo I et al (2015) Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: Retrospective Study and Systematic Review. Retina 35(8):1577\u20131593","journal-title":"Retina"},{"issue":"3","key":"6681_CR11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ajo.2012.09.020","volume":"155","author":"HM Kang","year":"2013","unstructured":"Kang HM, Kim YM, Koh HJ (2013) Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 155(3):438\u2013447","journal-title":"Am J Ophthalmol"},{"key":"6681_CR12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/OPTH.S171015","volume":"12","author":"K Takahashi","year":"2018","unstructured":"Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T et al (2018) Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clin Ophthalmol 12:1789\u20131799","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"6681_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P et al (2018) Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol 136(7):786\u2013793","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"6681_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0360-3016(96)00339-2","volume":"36","author":"LT Yonemoto","year":"1996","unstructured":"Yonemoto LT, Slater JD, Friedrichsen EJ, Loredo LN, Ing J, Archambeau JO et al (1996) Phase I\/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: treatment techniques and preliminary results. Int J Radiat Oncol Biol Phys 36(4):867\u2013871","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Pt 2","key":"6681_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/eye.2000.46","volume":"14","author":"CJ Flaxel","year":"2000","unstructured":"Flaxel CJ, Friedrichsen EJ, Smith JO, Oeinck SC, Blacharski PA, Garcia CA et al (2000) Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration. Eye 14(Pt 2):155\u2013164","journal-title":"Eye"},{"issue":"2","key":"6681_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000368561","volume":"233","author":"U Introini","year":"2015","unstructured":"Introini U, Casalino G, Triolo G, O\u2019Shaughnessy D, Shusterman EM, Chakravarthy U et al (2015) Stereotactic radiotherapy for polypoidal choroidal vasculopathy: a pilot study. Ophthalmologica 233(2):82\u201388","journal-title":"Ophthalmologica"},{"issue":"1","key":"6681_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40123-021-00409-3","volume":"11","author":"J Guo","year":"2022","unstructured":"Guo J, Qiu X, Tang W, Xu G, Moyers MF, Ren W et al (2022) One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study. Ophthalmol Ther 11(1):187\u2013199","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"6681_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P et al (2020) Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol 138(9):935\u2013942","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"6681_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1118\/1.598587","volume":"26","author":"MF Moyers","year":"1999","unstructured":"Moyers MF, Galindo RA, Yonemoto LT, Loredo L, Friedrichsen EJ, Kirby MA et al (1999) Treatment of macular degeneration with proton beams. Med Phys 26(5):777\u2013782","journal-title":"Med Phys"},{"issue":"1","key":"6681_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43\u201358","journal-title":"Am J Ophthalmol"},{"key":"6681_CR21","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/bjophthalmol-2013-304761","volume":"98","author":"L Chen","year":"2014","unstructured":"Chen L, Kim IK, Lane AM, Gauthier D, Munzenrider JE, Gragoudas ES et al (2014) Proton beam irradiation for non-AMD CNV: 2-year results of a randomised clinical trial. Br J Ophthalmol 98:1212\u20131217","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"6681_CR22","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y, Xu X, Liu X, Tang S et al (2014) Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121(9):1740\u20131747","journal-title":"Ophthalmology"},{"key":"6681_CR23","doi-asserted-by":"crossref","unstructured":"AURORA Study Group (2016) Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: Subgroup Analysis of the Aurora Study. Retina 36(5):926\u2013937","DOI":"10.1097\/IAE.0000000000000875"},{"issue":"6","key":"6681_CR24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00417-020-04988-y","volume":"259","author":"LH Ye","year":"2021","unstructured":"Ye LH, Cai Y, Shi X, Wong IYH, Qu JF, Zhao MW et al (2021) One-year results of intravitreal conbercept in treatment-naive subjects with polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 259(6):1455\u20131462","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"6681_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/IAE.0000000000002035","volume":"39","author":"Z Huang","year":"2019","unstructured":"Huang Z, Ding Q, Yan M, Lian H, Chen Z, Chen X et al (2019) Short-Term Efficacy of Conbercept and Ranibizumab for Polypoidal Choroidal Vasculopathy. Retina 39(5):889\u2013895","journal-title":"Retina"},{"issue":"3","key":"6681_CR26","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1111\/aos.15272","volume":"101","author":"X Li","year":"2023","unstructured":"Li X, Qu J, Su G, Yu S, Zhang Y, Sadda SV et al (2023) The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48-week randomized phase 4 study: STAR study. Acta Ophthalmol 101(3):e327-337","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"6681_CR27","first-page":"379","volume":"72","author":"M Morizane-Hosokawa","year":"2018","unstructured":"Morizane-Hosokawa M, Morizane Y, Kimura S, Shiode Y, Hirano M, Doi S et al (2018) Impact of Polyp Regression on 2-year Outcomes of Intravitreal Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal Choroidal Vasculopathy. Acta Med Okayama 72(4):379\u2013385","journal-title":"Acta Med Okayama"},{"issue":"1","key":"6681_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12886-023-03264-x","volume":"23","author":"J Lee","year":"2023","unstructured":"Lee J, Kim K, Kim ES, Yu SY, Kang MS (2023) Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression. BMC Ophthalmol 23(1):511","journal-title":"BMC Ophthalmol"},{"issue":"961\u2013972","key":"6681_CR29","doi-asserted-by":"publisher","first-page":"e961","DOI":"10.1016\/j.ajo.2011.01.002","volume":"151","author":"A Tsujikawa","year":"2011","unstructured":"Tsujikawa A, Ojima Y, Yamashiro K, Nakata I, Ooto S, Tamura H et al (2011) Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy. Am J Ophthalmol 151(961\u2013972):e961","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"6681_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00417-014-2707-2","volume":"253","author":"S Ijiri","year":"2015","unstructured":"Ijiri S, Sugiyama K (2015) Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 253(3):351\u2013357","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"6681_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ijrobp.2012.07.2352","volume":"85","author":"AU Kishan","year":"2013","unstructured":"Kishan AU, Modjtahedi BS, Morse LS, Lee P (2013) Radiation therapy for neovascular age-related macular degeneration. Int J Radiat Oncol Biol Phys 85(3):583\u2013597","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"6681_CR32","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ijrobp.2005.01.016","volume":"62","author":"B Damato","year":"2005","unstructured":"Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD (2005) Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys 62(5):1405\u20131411","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"6681_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1367-5931(99)80014-3","volume":"3","author":"EC Jonathan","year":"1999","unstructured":"Jonathan EC, Bernhard EJ, McKenna WG (1999) How does radiation kill cells? Curr Opin Chem Biol 3(1):77\u201383","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"6681_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/09553000410001692726","volume":"80","author":"ME Robbins","year":"2004","unstructured":"Robbins ME, Zhao W (2004) Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol 80(4):251\u2013259","journal-title":"Int J Radiat Biol"},{"issue":"7","key":"6681_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s004170100314","volume":"239","author":"AC Lambooij","year":"2001","unstructured":"Lambooij AC, Kuijpers RW, Mooy CM, Kliffen M (2001) Radiotherapy of exudative age-related macular degeneration; a clinical and pathologic study. Graefes Arch Clin Exp Ophthalmol 239(7):539\u2013543","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"6681_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/02713688908996381","volume":"8","author":"U Chakravarthy","year":"1989","unstructured":"Chakravarthy U, Gardiner TA, Archer DB, Maguire CJ (1989) A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds. Curr Eye Res 8(4):337\u2013348","journal-title":"Curr Eye Res"},{"issue":"6","key":"6681_CR37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/bjo.79.6.562","volume":"79","author":"PM Hart","year":"1995","unstructured":"Hart PM, Archer DB, Chakravarthy U (1995) Asymmetry of disciform scarring in bilateral disease when one eye is treated with radiotherapy. Br J Ophthalmol 79(6):562\u2013568","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"6681_CR38","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S0360-3016(97)00919-X","volume":"40","author":"JO Archambeau","year":"1998","unstructured":"Archambeau JO, Mao XW, Yonemoto LT, Slater JD, Friedrichsen E, Teichman S et al (1998) What is the role of radiation in the treatment of subfoveal membranes: review of radiobiologic, pathologic, and other considerations to initiate a multimodality discussion. Int J Radiat Oncol Biol Phys 40(5):1125\u20131136","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"6681_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.oret.2016.11.003","volume":"1","author":"S Osmanovic","year":"2017","unstructured":"Osmanovic S, Moisseiev E, Mishra KK, Daftari I, Moshiri A, Morse L et al (2017) Phase I\/II Randomized Study of Proton Beam with Anti-Vascular Endothelial Growth Factor for Exudative Age-Related Macular Degeneration: One-Year Results. Ophthalmol Retina 1(3):217\u2013226","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"6681_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27(7):787\u2013794","journal-title":"Eye (Lond)"},{"issue":"8","key":"6681_CR41","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0161-6420(92)31832-9","volume":"99","author":"DR Guyer","year":"1992","unstructured":"Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, Gragoudas ES (1992) Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology 99(8):1278\u20131285","journal-title":"Ophthalmology"},{"issue":"4","key":"6681_CR42","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ijrobp.2007.11.045","volume":"70","author":"PT Finger","year":"2008","unstructured":"Finger PT (2008) Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 70(4):974\u2013977","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"6681_CR43","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1158\/1078-0432.CCR-03-0426","volume":"10","author":"RA Nordal","year":"2004","unstructured":"Nordal RA, Nagy A, Pintilie M, Wong CS (2004) Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 10(10):3342\u20133353","journal-title":"Clin Cancer Res"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06681-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T12:51:09Z","timestamp":1743511869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06681-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6681"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06681-w","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was provided by the Ethics Committee of the Eye and ENT Hospital of Fudan University (No. 2018029\u20131) and this study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no conflict of interest to declare. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}